EUVIMEDEUVIMED entdecken
Crossref

Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma

Xiaoqing Sun, Jianghua Cao, Peng Sun, Hang Yang, Huan Li, Wenjuan Ma, Xianqiu Wu, Xiaohua He, Jing Li, Zhiming Li iD, Jiajia Huang iD

Biomarkers in Medicine · 2023

DOI: 10.2217/bmm-2022-0764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomarkers in Medicine, 2023. Verfasst von Xiaoqing Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit(ICU), State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR …. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To explore the clinical association between soluble Siglec-5/CD163 and clinical feature and prognosis in peripheral blood samples of patients with diffuse large B-cell lymphoma.

Method

Significantly elevated cytokines in peripheral blood were characterized by cytokines array and validated by ELISA.

Results

Compared with CD163, Siglec-5 exhibited superiority in discriminating patients into low- and high-risk subgroups based on overall survival and progression-free survival. In addition, Siglec-5 was an indicator of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment efficacy.

Conclusion

Siglec-5 may be applied as a reliable independent immune indicator for overall survival and progression-free survival. It may also predict R-CHOP efficacy in diffuse large B-cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseHumansRituximabDisease-Free SurvivalVincristinePrednisoneTreatment OutcomePrognosisCyclophosphamideDoxorubicinCytokinesSialic Acid Binding Immunoglobulin-like Lectins

Stichwörter der Autor:innen

CD163DLBCLSiglec-5peripheral bloodprognostic

Substanzen

RituximabVincristinePrednisoneCyclophosphamideDoxorubicinCytokinesSialic Acid Binding Immunoglobulin-like Lectins

Autor:innen und Institutionen

  • Department of Intensive Care Unit(ICU), State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
  • Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

ORCID-Profile: Zhiming Li, Jiajia Huang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Sun, X., Cao, J., Sun, P., Yang, H., Li, H., Ma, W., Wu, X., He, X., Li, J., Li, Z., & Huang, J. (2023). Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2022-0764

Vancouver

Sun X, Cao J, Sun P, Yang H, Li H, Ma W, et al. Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma. Biomarkers in Medicine. 2023. doi:10.2217/bmm-2022-0764

BibTeX
@article{Sun2023,
  author = {Sun, Xiaoqing and Cao, Jianghua and Sun, Peng and Yang, Hang and Li, Huan and Ma, Wenjuan and Wu, Xianqiu and He, Xiaohua and Li, Jing and Li, Zhiming and Huang, Jiajia},
  title = {Pretreatment Soluble Siglec-5 Protein Predicts Early Progression and R-Chop Efficacy in Diffuse Large B-Cell Lymphoma},
  journal = {Biomarkers in Medicine},
  year = {2023},
  doi = {10.2217/bmm-2022-0764}
}
Kostenlos starten →